News about Drug Discovery & Development

Galderma Launches First OBT-Based Restylane Injectables in Japan

Galderma has launched Restylane Defyne and Restylane Refyne in Japan, marking the first authorization of hyaluronic acid injectables powered by its proprietary Optimal Balance Technology (OBT) in the country.

Drug Discovery & Development | 12/02/2026 | By Darshana |  134

Barzolvolimab Shows Sustained, Off-Treatment Benefits in Chronic Spontaneous Urticaria at AAAAI 2026

Phase II data presented at AAAAI 2026 show barzolvolimab achieved rapid, durable complete responses in chronic spontaneous urticaria, with sustained disease control observed months after treatment discontinuation.

Drug Discovery & Development | 12/02/2026 | By News Bureau |  208

Novo Nordisk Plans Wegovy Vial Launch to Expand Obesity Care Options

Danish drugmaker Novo Nordisk is planning to introduce vial presentations of its blockbuster obesity treatment Wegovy (semaglutide), expanding the range of delivery formats available for the therapy as competition intensifies in the weight-management market.

Drug Discovery & Development | 12/02/2026 | By Darshana |  164

Takeda's Oveporexton NDA Accepted by US FDA with Priority Review for Narcolepsy Type 1

FDA grants Priority Review to Takeda’s investigational orexin receptor agonist oveporexton (TAK-861) for narcolepsy type 1, with a PDUFA decision expected in Q3 this year.

Drug Discovery & Development | 11/02/2026 | By News Bureau |  130

FDA Grants Breakthrough Therapy Designation to Sanofi's Wayrilz for Rare Blood Disorder wAIHA

The US FDA has granted breakthrough therapy designation to Wayrilz (rilzabrutinib) for warm autoimmune haemolytic anaemia, while Japan’s health ministry awarded orphan status, accelerating development for the rare disorder.

Drug Discovery & Development | 11/02/2026 | By News Bureau |  146

MerryLife Biomedical Reports Positive Phase I Data for Oral Alzheimer's Therapy TML-6

MerryLife Biomedical’s investigational oral therapy TML-6 demonstrated favourable safety and tolerability in Phase I, paving the way for a 210-patient global Phase II trial in early Alzheimer’s disease.

Drug Discovery & Development | 10/02/2026 | By News Bureau |  104

Innovent Biologics and Eli Lilly Forge Strategic Collaboration in Oncology and Immunology

Innovent Biologics will receive USD 350 million upfront and up to USD 8.5 billion in milestones under a new global development pact, with Lilly securing ex-Greater China rights to novel oncology and immunology programmes.

Drug Discovery & Development | 10/02/2026 | By News Bureau |  105

India Begins First Human Trials of Indigenous KFD Vaccine

The Indian Council of Medical Research (ICMR), in partnership with Indian Immunologicals, has advanced an indigenous vaccine candidate for Kyasanur Forest Disease (KFD), commonly known as monkey fever, into Phase I human clinical trials.

Drug Discovery & Development | 09/02/2026 | By Darshana |  176

FDA Grants Orphan Drug Designation to Zenocutuzumab for Rare Cholangiocarcinoma Subset

Partner Therapeutics secures Orphan Drug Designation for zenocutuzumab-zbco in NRG1 fusion-positive cholangiocarcinoma, strengthening development of targeted therapy for this aggressive rare cancer.

Drug Discovery & Development | 09/02/2026 | By News Bureau |  132

Evogene's Biomica Signs Global Licensing Deal with Lishan Biotech for Microbiome-Based Cancer Therapy BMC128

Lishan Biotech secures exclusive worldwide rights to develop and commercialise BMC128, a Phase I microbiome-based immunotherapy candidate showing early promise in lung and renal cancers.

Drug Discovery & Development | 07/02/2026 | By News Bureau |  101